novo nordisk semaglutide alzheimer trial GLP-1 Drug Fails to Improve Alzheimer's Symptoms, Scientists Remain Hopeful Semaglutide fails to slow cognitive

These schedules provide a template for safe, effective use

Long-Term Health Improvements Patients who incorporate lifestyle changes, such as healthier eating habits and regular physical activity, often see better long-term results with GLP-1 medications

Patients prescribed the 2.5 mg starting dose should be aware that BCBS plans typically authorize the full titration schedule (2.5 mg for 4 weeks, then 5 mg, then potential increases to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) under one PA approval

Many patients begin seeing noticeable weight loss within the first 4 to 6 weeks, with continued progress over several months when paired with healthy habits